This article is more than 5 years old. Information may no longer be current.

FDA to review Eylea for diabetic retinopathy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has agreed to review a supplemental biologics license application of Eylea for the treatment of diabetic retinopathy, Regeneron announced in a press release.

Data from the phase 3 PANORAMA trial found positive top-line results for Eylea (aflibercept) injection after 6 months in patients with moderately severe to severe nonproliferative diabetic retinopathy without diabetic macular edema. The sBLA submission was based on data from this trial, according to the release.

The FDA’s target action date for a decision is May 13, 2019.